Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,443 across all filing types
Latest filing 2019-04-02 Regulatory Filings
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
IMU presents new mimotope PD-1 vaccine data at AACR 2 pages 160.0KB
Regulatory Filings Classification · 90% confidence The document is an ASX announcement from Imugene Limited presenting positive new data on a cancer vaccine at a scientific conference (American Association for Cancer Research 2019 Annual Meeting). It highlights research findings and details about the presentation but does not contain financial data, regulatory filings, or management changes. The document is relatively short (3910 characters) and focuses on scientific and clinical progress rather than financial or corporate governance matters. It is not a report itself but an announcement of research results presented at a conference. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2019-04-02 English
IMU presents positive new HER-Vaxx data at AACR 3 pages 166.9KB
Regulatory Filings Classification · 90% confidence The document is an ASX announcement presenting new data from a Phase Ib clinical trial of Imugene's HER-Vaxx cancer vaccine. It includes detailed clinical trial results, safety data, and mentions the initiation of a Phase II study. The content is focused on clinical trial data presentation rather than financial results or regulatory filings. It is not a full financial report, earnings release, or management discussion. The document is a detailed announcement of clinical trial progress and data, typical of a Capital/Financing Update or Regulatory Filing. However, since it is an ASX announcement primarily about clinical trial data and not about financing or capital structure changes, the best fit is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories. The document length (6121 characters) and detailed content confirm it is not a brief report publication announcement or a short notice. Therefore, the classification is RNS with high confidence.
2019-04-01 English
IMU presents new KEY-Vaxx and B-Vaxx data at AACR 3 pages 164.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited presenting new data on their cancer vaccine programs at a scientific conference (American Association for Cancer Research 2019 Annual Meeting). It discusses clinical trial data, vaccine efficacy, and research collaborations. There is no indication that this is a financial report, earnings release, regulatory filing, or management discussion. The content is primarily a corporate announcement about scientific data presentation, which fits best under a general regulatory announcement category. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2019-04-01 English
Investor Presentation 25 pages 1.0MB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation March 2019' and contains detailed information about the company's immuno-oncology approach, market opportunity, clinical pipeline, leadership team, and strategic direction. It includes forward-looking statements, market data, clinical trial phases, and investment highlights. The content is structured as a presentation aimed at investors, focusing on financials, strategy, and market position rather than being a formal regulatory filing or financial report. There is no indication that this is an annual report, earnings release, or regulatory filing. The length (15,000 characters) and detailed content support it being a full investor presentation rather than a brief announcement or summary. Therefore, the appropriate classification is Investor Presentation (IP).
2019-03-25 English
IMU Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx 2 pages 76.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited regarding the receipt and acceptance of minutes from a Pre-IND meeting with the FDA. It discusses regulatory guidance for clinical development plans of a cancer immunotherapy product. The content is a regulatory update about a meeting with the FDA and does not contain financial statements, earnings data, or detailed financial analysis. It is not a full report like an Annual Report or Interim Report, nor is it a call transcript or management report. The document is relatively short (3585 characters) and serves as an announcement of regulatory progress and guidance received. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-03-19 English
Imugene doses first patient in HER-Vaxx phase 2 trial 3 pages 97.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited dated 14 March 2019, announcing the dosing of the first patient in a Phase 2 clinical trial for their HER-Vaxx cancer vaccine. The content focuses on clinical trial progress, recruitment updates, and study design details. There are no financial statements, earnings data, or regulatory filings related to financial performance. The document is a corporate announcement about a clinical trial milestone rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Earnings Release, or Regulatory Filings. It is an announcement of a clinical development milestone, which aligns best with a general Regulatory Filings (RNS) category as a miscellaneous corporate announcement that does not fit other specific categories.
2019-03-13 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.